Biomarker identification in human pancreatic cancer sera

Pancreas

Volumn 36, Issue 1, 2008, Pages 61-69

  Hanas, Jay S ^a,d   Hocker, James R ^a   Cheung, John Y ^b   Larabee, Jason L ^a   Lerner, Megan R ^a,c   Lightfoot, Stan A ^a   Morgan, Daniel L ^a   Denson, Kent D ^a   Prejeant, Kristi C ^a   Gusev, Yuiry ^a   Smith, Brenda J ^a   Hanas, Rushie J ^a   Postier, Russell G ^a   Brackett, Daniel J ^a,c  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b University of Oklahoma   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Laboratory 448   (United States)

Author keywords

Biomarkers; Cancer heterogeneity; Electrospray ionization mass spectrometry; Pancreatic cancer; Serum profiling

Indexed keywords

ALPHA 2 MACROGLOBULIN; CERULOPLASMIN; COMPLEMENT COMPONENT C3C; TRYPSIN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BOOTSTRAPPING; CANCER PATIENT; CELL HETEROGENEITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ELECTROSPRAY; FEMALE; GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; ION TRAP MASS SPECTROMETRY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADENOCARCINOMA; ADULT; AGED; ALPHA-MACROGLOBULINS; AMINO ACID SEQUENCE; CERULOPLASMIN; COMPLEMENT C3C; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HISTOCYTOCHEMISTRY; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; PANCREATIC NEOPLASMS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRYPSIN; TUMOR MARKERS, BIOLOGICAL;

EID: 38149013132     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e3180d0a738     Document Type: Article

References (34)

1. American Cancer Society, 2006. Available at: http://www.cancer.org/ downloads/STT/CAFF2006PWSecured.pdf. Accessed August 2006.
2. Schroder FH, Roobol MJ, Damhuis RA, et al. Rotterdam randomized pilot studies of screening for prostate cancer - an overview after 10 years. J Natl Cancer Inst. 2005;97:696. [Cancer 1996;78:57-62].
3. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
4. Postier RG. Past, present, and future of pancreatic surgery. Am J Surg. 2001;182:547-551.
5. Lowenfels AB, Maisonneuve P, Lankisch PG. Chronic pancreatitis and other risk factors for pancreatic cancer. Gastroenterol Clin North Am. 1999;28:673-685.
6. Postier RG, Lerner MR, Lightfoot SA, et al. DNA ploidy and Markovian analysis of Neoplastic progression in experimental pancreatic cancer. J Histochem Cytochem. 2003;51:303-309.
7. Gattani AM, Mandeli J, Bruckner HW. Tumor markers in patients with pancreatic carcinoma. Cancer. 1996;78:57-62.
8. Ulrich AB, Schmied BM, Standop J, et al. Differences in the expression of glutathione S-transferases in normal pancreas, chronic pancreatitis, secondary chronic pancreatitis, and pancreatic cancer. Pancreas. 2002;24:291-297.
9. Trachte AL, Suthers SE, Lerner ME, et al. Increased expression of alpha-1-antitrypsin, glutathione S-transferase, and vascular endothelial growth factor in human pancreatic adenocarcinoma. Am J Surg. 2002;184:642-647.
10. Wang W, Abbruzzese JL, Evans DB, et al. The nuclear factor-kappa B Rel A transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res. 1999;5:119-127.
11. Chambers G, Lawrie L, Cash P, et al. Proteomics: a new approach to the study of disease. J Pathol. 2000;192:280-288.
12. Verma M, Wright GL Jr, Hanash SM, et al. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann N Y Acad Sci. 2001;945:103-115.
13. Valerio A, Basso D, Mazza S, et al. Serum protein profiles of patients with pancreatic cancer and chronic pancreatitis: searching for a diagnostic protein pattern. Rapid Commun Mass Spectrom. 2001;15:2420-2425.
14. Li J, Zhang Z, Rosenzweig J, et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002;48:1296-1304.
15. Ornstein DK, Rayford W, Fusaro VA, et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol. 2004;172:1302-1305.
16. Exocrine pancreas. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002: 157-164.
17. Larabee JL, Hocker JR, Lerner MR, et al. Stress induced in heart and other tissues by rat dermal exposure to JP-8 fuel. Cell Biol Toxicol. 2005;21:233-246.
18. Dittmer GAG, Wilkinson CRM, Jedrzejewski PT, et al. Role of a ubiquitin-like modification in polarized morphogenesis. Science. 2002;295:2442-2446.
19. Zharkikh A, Wen-Hsiung L. Statistical properties of bootstrap estimation phylogenetic variability from nucleotide sequences. I. Four taxa with a molecular clock. Mol Biol Evol. 1992;9:1119-1147.
20. MathWorks, Inc. Matlab User's Guide. Natick, MA: MathWorks, Inc; 2002.
21. James ML, Smith GM, Wolford JC. Applied Numerical Methods For Digital Computation. New York, NY: Harper & Row Publishers; 1985.
22. Samso M, Palumbo MJ, Radermacher M, et al. A Bayesian method for classification of images from electron micrographs. J Struct Biol. 2002;138:157-170.
23. Engstrom G, Hedblad B, Stavenow L, et al. Fatality of future coronary events is related to inflammation-sensitive plasma proteins: a population-based prospective cohort study. Circulation. 2004;110:27-31.
24. Richter R, Schuz-Knappe P, Schrader M, et al. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatogr B Biomed Sci Appl. 1999;726:25-35.
25. Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem. 2005;51:102-112.
26. Yu Y, Chen S, Wang LS, et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology. 2005;68:79-86.
27. Koomen JM, Shih LN, Coombes KR, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res. 2005;11:1110-1118.
28. Szalai AJ, van Ginkel FW, Wang Y, et al. Complement-dependent acute-phase expression of C-reactive protein and serum amyloid P-component. J Immunol. 2000;165:1030-1035.
29. Nakae Y, Hayakawa T, Kondo T, et al. Diagnostic value of serum level of alpha 2-macroglobulin-trypsin complex in pancreatic diseases using a colorimetric assay with a synthetic chromogenic substrate. Nippon Shokakibyo Gakkai Zasshi. 1991;88:2853-2860.
30. Ikari Y, Fujikawa K, Yee KO, et al. Alpha(1)-proteinase inhibitor, alpha(1)-antichymotrypsin, or alpha(2)-macroglobulin is required for vascular smooth muscle cell spreading in three-dimensional fibrin gel. J Biol Chem. 2000;275:12799-12805.
31. Tan Z-J, Hu X-G, Cao G-S, et al. Analysis of gene expression profile of pancreatic carcinoma using cDNA microarray. World J Gastroenterol. 2003;9:818-823.
32. Lee CM, Lo HW, Shao RP, et al. Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. Cancer Res. 2004;64:1788-1793.
33. Teknos TN, Islam M, Arenberg DA, et al. The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2005;131:204-211.
34. Kittiniyom K, Gorse KM, Dalbegue F, et al. Allelic loss on chromosome band 18p11.3 occurs early and reveals heterogeneity in breast cancer progression. Breast Cancer Res. 2001;3:192-198.